ArticleJournal of cardiothoracic surgery2025
Efficacy of hemadsorption combining with cardiopulmonary bypass used in patients with acute type A aortic dissection.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIt is hypothesized that combining HA380 with cardiopulmonary bypass (CPB) in acute type A aortic dissection (ATAAD) surgery could reduce the inflammatory response induced by CPB and subsequently improve prognosis.? Therefore, we aimed to assess the short-term effectiveness of combining HA380 with CPB in treating ATAAD.
methodsThis study exclusively included individuals diagnosed with ATAAD at our institution from January 2021 to April 2023. After propensity score matching (PSM), patients were allocated into two groups: the hemadsorption (HA) group (n = 45) and the control group (n = 45). The outcome measures included commonly used clinical inflammatory markers, coagulation function, liver and kidney function, ventilator time, and time of ICU stay duration.
resultsPatients in the HA group exhibited elevated postoperative levels of procalcitonin and systemic coagulation-inflammation index (SCI), along with lower white blood cell counts and blood urea nitrogen levels compared to the control group. The HA group had a significantly higher 60-day postoperative survival rate compared to the control group. While the HA group experienced reduced in-hospital mortality and stroke incidence, only the reduction in stroke incidence showed a significant association with the intervention after adjusting for confounders.
conclusionThe application of HA380 does not significantly reduce all postoperative inflammatory indicators in ATAAD surgery. The reduction in inflammatory response was also not obvious. However, it was associated with a significantly lower stroke incidence and improved 60-day survival, suggesting potential clinical benefits in specific outcomes. The specific mechanisms underlying the lower rates of stroke and mortality require further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.